

Medical or Research Professionals/Clinicians

Topic area: Clinical topics by disease

Specific topic: 12. Rheumatoid arthritis - comorbidity and clinical aspects

EULAR15-3244

PREVALENCE OF CARDIOVASCULAR DISEASE AND ITS ASSOCIATIONS WITH DISEASE SEVERITY IN RHEUMATOID ARTHRITIS PATIENTS – DATA FROM THE ONTARIO BEST PRACTICES RESEARCH INITIATIVE (OBRI)

K. Cui^{1,2,*}, B. Jacob¹, J. Widdifield³, J. Pope⁴, B. Kuriya^{2,5}, P. Akhavan⁵, C. Bombardier^{1,2,5}

¹Toronto General Hospital Research Institute, ²Faculty of Medicine, University of Toronto, ³Institute for Clinical Evaluative Science, Toronto, ⁴Medicine, University of Western Ontario, London, ⁵Division of Rheumatology, Mount Sinai Hospital, Toronto, Canada

My abstract has been or will be presented at a scientific meeting during a 12 months period prior to EULAR 2015:

Yes

Abstract presented or will be presented at (meeting): Canadian Rheumatology Association Annual Meeting

Is the first author applying for a travel bursary or an award for undergraduate medical students?: Yes - Abstract award for undergraduate medical students

Is the first author of this abstract an undergraduate medical student?: Yes

Background: Cardiovascular disease (CVD) is a major comorbidity and the leading cause of death among patients with rheumatoid arthritis (RA)¹.

Objectives: To compare the demographics, patterns of medication use, and disease activity in RA patients with and without CVD at cohort entry and 12 months of follow-up.

Methods: Physician and patient-reported data were collected from the Ontario Best Practices Research Initiative Rheumatoid Arthritis Registry (OBRI- RA), a clinical registry of RA patients followed in routine care. CVD was defined as the presence of coronary artery disease (CAD), congestive heart failure (CHF), hypertension (HTN), arrhythmia, stroke, transient ischemic attack (TIA), and/or other heart disorders upon entering the registry. Patient demographics, clinical characteristics, socioeconomic status and treatment regimens were compared between CVD and non-CVD patients at cohort entry using Chi-square and t-tests. Mean disease activity and functional status scores at cohort entry and 12 months of follow-up were estimated by generalized linear regression, adjusting for confounders, including age, sex, smoking, socioeconomic factors, disease activity at cohort entry (for 12-month follow-up analyses only), and RA duration.

Results: Among 2226 RA patients, 360 (16.2%) had CVD at cohort entry. Among which, 101 (28.1%) had CAD, 51 (14.2%) had arrhythmia, 12 (3.3%) had CHF, 28 (7.8%) had CVA, 8 (2.2%) had PE, and 160 (44.4%) had other/unspecified CVD. Patients with CVD were older (66.7 ± 10.1 vs. 53.6 ± 12.9 yrs, $p < 0.0001$), had longer RA duration (10.6 ± 11.8 vs. 8.1 ± 9.0 yrs, $p < 0.0001$) and more extra-articular features (35.0% vs. 26.3%, $p < 0.05$). Male sex, lower education and income, lack of private insurance, and smokers were more frequent among CVD patients ($p < 0.001$ for all). CVD patients were more frequently treated with glucocorticoids (34.9% vs. 28.3%, $p < 0.05$) but less frequently with NSAIDs (29.9% vs. 49.3%, $p < 0.05$). After adjusting for confounders, patients with CVD had higher RADAI and HAQ-DI, but similar DAS28, CDAl, or SDAI scores at cohort entry, and at 12 months, CVD patients were more likely to have significantly higher DAS28 and ESR than patients without CVD.

Conclusions: At cohort entry, RA patients with CVD have worse disease activity (RADAI) and functional status (HAQ-DI). At 12 months of follow-up, disease activity (DAS28) remained worse among CVD patients. The higher ESR found in CVD patients may suggest heightened systemic inflammation¹. The lower use of NSAIDs may be due to their known CVD risks, but the higher utilization of glucocorticoids may require further investigation.

References: 1. Choy E, Ganeshalingam K, Semb AG, et al. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment.

Rheumatology (2014) 53 (12):2143-2154.

Acknowledgements: Dr. Bombardier holds a Canada Research Chair in Knowledge Transfer for Musculoskeletal Care and a Pfizer Research Chair in Rheumatology. We also thank the OBRI investigators for ongoing data collection for the OBRI registry.

Disclosure of Interest: None declared